Psoríase

Referências

Principais artigos

Griffiths CE, Christophers E, Barker JN, et al. A classification of psoriasis vulgaris according to phenotype. Br J Dermatol. 2007 Feb;156(2):258-62. Resumo

Chiricozzi A, Pimpinelli N, Ricceri F, et al. Treatment of psoriasis with topical agents: recommendations from a Tuscany consensus. Dermatol Ther. 2017 Nov;30(6). Resumo

Lebwohl M. A clinician's paradigm in the treatment of psoriasis. J Am Acad Dermatol. 2005 Jul;53(1 suppl 1):S59-69. Resumo

Gisondi P, Altomare G, Ayala F, et al. Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2017 May;31(5):774-90.Texto completo  Resumo

Artigos de referência

1. Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2013 Nov;69(5):729-35. Resumo

2. Griffiths CE, Christophers E, Barker JN, et al. A classification of psoriasis vulgaris according to phenotype. Br J Dermatol. 2007 Feb;156(2):258-62. Resumo

3. Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019 Jan;80(1):251-65. Resumo

4. Parisi R, Iskandar IYK, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020 May 28;369:m1590.Texto completo  Resumo

5. Gibbs S. Skin disease and socioeconomic conditions in rural Africa: Tanzania. Int J Dermatol. 1996 Sep;35(9):633-9. Resumo

6. Danielsen K, Olsen AO, Wilsgaard T, et al. Is the prevalence of psoriasis increasing? A 30-year follow-up of a population-based cohort. Br J Dermatol. 2013 Jun;168(6):1303-10. Resumo

7. Armstrong AW, Mehta MD, Schupp CW, et al. Psoriasis prevalence in adults in the United States. JAMA Dermatol. 2021 Aug 1;157(8):940-6. Resumo

8. Springate DA, Parisi R, Kontopantelis E, et al. Incidence, prevalence and mortality of patients with psoriasis: a U.K. population-based cohort study. Br J Dermatol. 2017 Mar;176(3):650-8.Texto completo  Resumo

9. Mercy K, Paller AS. Practice gaps. Prescribing patterns by dermatologists and primary care providers for pediatric psoriasis: comment on "Trends in pediatric psoriasis outpatient health care delivery in the United States". Arch Dermatol. 2012 Jan;148(1):71-2. Resumo

10. Elder JT, Nair RP, Guo SW, et al. The genetics of psoriasis. Arch Dermatol. 1994 Feb;130(2):216-24. Resumo

11. Lønnberg AS, Skov L, Skytthe A, et al. Heritability of psoriasis in a large twin sample. Br J Dermatol. 2013 Aug;169(2):412-6. Resumo

12. Deng Y, Chang C, Lu Q. The inflammatory response in psoriasis: a comprehensive review. Clin Rev Allergy Immunol. 2016 Jun;50(3):377-89. Resumo

13. Dand N, Mahil SK, Capon F, et al. Psoriasis and genetics. Acta Derm Venereol. 2020 Jan 30;100(3):adv00030.Texto completo  Resumo

14. Prieto-Pérez R, Cabaleiro T, Daudén E, et al. Genetics of psoriasis and pharmacogenetics of biological drugs. Autoimmune Dis. 2013;2013:613086.Texto completo  Resumo

15. Bowcock AM, Barker JN. Genetics of psoriasis: the potential impact of new therapies. J Am Acad Dermatol. 2003 Aug;49(2 suppl):S51-6. Resumo

16. Schon MP, Boehncke WH. Psoriasis. N Engl J Med. 2005 May 5;352(18):1899-912. Resumo

17. Philipp S, Wolk K, Kreutzer S, et al. The evaluation of psoriasis therapy with biologics leads to a revision of the current view of the pathogenesis of this disorder. Expert Opin Ther Targets. 2006 Dec;10(6):817-31. Resumo

18. Mehlis SL, Gordon KB. The immunology of psoriasis and biologic immunotherapy. J Am Acad Dermatol. 2003 Aug;49(2 suppl):S44-50. Resumo

19. Gudjonsson JE, Thorarinsson AM, Sigurgeirsson B, et al. Streptococcal throat infections and exacerbation of chronic plaque psoriasis: a prospective study. Br J Dermatol. 2003 Sep;149(3):530-4. Resumo

20. Weinstein GD, McCullough JL, Ross PA. Cell kinetic basis for pathophysiology of psoriasis. J Invest Dermatol. 1985 Dec;85(6):579-83.Texto completo  Resumo

21. Nestle FO, Di Meglio P, Qin JZ, et al. Skin immune sentinels in health and disease. Nat Rev Immunol. 2009 Oct;9(10):679-91. Resumo

22. Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009 Jun;129(6):1339-50. Resumo

23. Lynde CW, Poulin Y, Vender R, et al. Interleukin 17A: toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol. 2014 Jul;71(1):141-50. Resumo

24. Martin DA, Towne JE, Kricorian G, et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol. 2013 Jan;133(1):17-26. Resumo

25. Lande R, Botti E, Jandus C, et al. The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat Commun. 2014 Dec 3;5:5621. Resumo

26. Arakawa A, Siewert K, Stöhr J, et al. Melanocyte antigen triggers autoimmunity in human psoriasis. J Exp Med. 2015 Dec 14;212(13):2203-12. Resumo

27. Krueger JG. An autoimmune "attack" on melanocytes triggers psoriasis and cellular hyperplasia. J Exp Med. 2015 Dec 14;212(13):2186. Resumo

28. Cheung KL, Jarrett R, Subramaniam S, et al. Psoriatic T cells recognize neolipid antigens generated by mast cell phospholipase delivered by exosomes and presented by CD1a. J Exp Med. 2016 Oct 17;213(11):2399-412. Resumo

29. Boyd AS, Neldner KH. The isomorphic response of Koebner. Int J Dermatol. 1990 Jul-Aug;29(6):401-10. Resumo

30. Song G, Yoon HY, Yee J, et al. Antihypertensive drug use and psoriasis: a systematic review, meta- and network meta-analysis. Br J Clin Pharmacol. 2021 Oct 5 [Epub ahead of print]. Resumo

31. Armstrong AW. Psoriasis provoked or exacerbated by medications: identifying culprit drugs. JAMA Dermatol. 2014 Sep;150(9):963. Resumo

32. Wu S, Han J, Li WQ, et al. Hypertension, antihypertensive medication use, and risk of psoriasis. JAMA Dermatol. 2014 Sep;150(9):957-63.Texto completo  Resumo

33. Russo PA, Ilchef R, Cooper AJ. Psychiatric morbidity in psoriasis: a review. Australas J Dermatol. 2004 Aug;45(3):155-9. Resumo

34. Naldi L, Chatenoud L, Linder D, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol. 2005 Jul;125(1):61-7. Resumo

35. Armstrong AW, Harskamp CT, Dhillon JS, et al. Psoriasis and smoking: a systematic review and meta-analysis. Br J Dermatol. 2014 Feb;170(2):304-14. Resumo

36. Richer V, Roubille C, Fleming P, et al. Psoriasis and smoking: a systematic literature review and meta-analysis with qualitative analysis of effect of smoking on psoriasis severity. J Cutan Med Surg. 2016 May;20(3):221-7. Resumo

37. Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014 Mar;70(3):512-6. Resumo

38. Zhu KJ, Zhu CY, Fan YM. Alcohol consumption and psoriatic risk: a meta-analysis of case-control studies. J Dermatol. 2012 Sep;39(9):770-3. Resumo

39. Brenaut E, Horreau C, Pouplard C, et al. Alcohol consumption and psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2013 Aug;27 (Suppl 3):30-5.Texto completo  Resumo

40. Cassano N, Vestita M, Apruzzi D, et al. Alcohol, psoriasis, liver disease, and anti-psoriasis drugs. Int J Dermatol. 2011 Nov;50(11):1323-31. Resumo

41. Parisi R, Webb RT, Carr MJ, et al. Alcohol-related mortality in patients with psoriasis: a population-based cohort study. JAMA Dermatol. 2017 Dec 1;153(12):1256-62.Texto completo  Resumo

42. Mahil SK, McSweeney SM, Kloczko E, et al. Does weight loss reduce the severity and incidence of psoriasis or psoriatic arthritis? A critically appraised topic. Br J Dermatol. 2019 Nov;181(5):946-53. Resumo

43. Budu-Aggrey A, Brumpton B, Tyrrell J, et al. Evidence of a causal relationship between body mass index and psoriasis: A mendelian randomization study. PLoS Med. 2019 Jan;16(1):e1002739.Texto completo  Resumo

44. Aune D, Snekvik I, Schlesinger S, et al. Body mass index, abdominal fatness, weight gain and the risk of psoriasis: a systematic review and dose-response meta-analysis of prospective studies. Eur J Epidemiol. 2018 Dec;33(12):1163-78.Texto completo  Resumo

45. Snekvik I, Nilsen TIL, Romundstad PR, et al. Metabolic syndrome and risk of incident psoriasis: prospective data from the HUNT Study, Norway. Br J Dermatol. 2019 Jan;180(1):94-9. Resumo

46. Davidovici BB, Sattar N, Prinz J, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010 Jul;130(7):1785-96.Texto completo  Resumo

47. Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005 Mar;64(suppl 2):ii65-8.Texto completo  Resumo

48. Cabrera S, Chinniah N, Lock N, et al. Inter-observer reliability of the PASI in a clinical setting. Australas J Dermatol. 2015 May;56(2):100-2. Resumo

49. Tillett W, Orbai AM, Ogdie A, et al. GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies. Ann Rheum Dis. 2018 May;77(5):e23. Resumo

50. Reich K, Krüger K, Mössner R, et al. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol. 2009 May;160(5):1040-7. Resumo

51. Strober B, Ryan C, van de Kerkhof P, et al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol. 2020 Jan;82(1):117-22.Texto completo  Resumo

52. Bailey JW. Topical treatments for chronic plaque psoriasis. Am Family Physician. 2010 Mar 1;81(5):596.Texto completo  Resumo

53. Chiricozzi A, Pimpinelli N, Ricceri F, et al. Treatment of psoriasis with topical agents: recommendations from a Tuscany consensus. Dermatol Ther. 2017 Nov;30(6). Resumo

54. Schlager JG, Rosumeck S, Werner RN, et al. Topical treatments for scalp psoriasis. Cochrane Database Syst Rev. 2016 Feb 26;(2):CD009687.Texto completo  Resumo

55. Samarasekera EJ, Sawyer L, Wonderling D, et al. Topical therapies for the treatment of plaque psoriasis: systematic review and network meta-analyses. Br J Dermatol. 2013 May;168(5):954-67.Texto completo  Resumo

56. Mason AR, Mason J, Cork M, et al. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev. 2013 Mar 28;(3):CD005028.Texto completo  Resumo

57. Devaux S, Castela A, Archier E, et al. Topical vitamin D analogues alone or in association with topical steroids for psoriasis: a systematic review. J Eur Acad Dermatol Venereol. 2012 May;26 (Suppl 3):52-60. Resumo

58. Lebwohl M. A clinician's paradigm in the treatment of psoriasis. J Am Acad Dermatol. 2005 Jul;53(1 suppl 1):S59-69. Resumo

59. van de Kerkhof P, de Peuter R, Ryttov J, et al. Mixed treatment comparison of a two-compound formulation (TCF) product containing calcipotriol and betamethasone dipropionate with other topical treatments in psoriasis vulgaris. Curr Med Res Opin. 2011 Jan;27(1):225-38. Resumo

60. Bottomley JM, Taylor RS, Ryttov J, et al. The effectiveness of two-compound formulation calcipotriol and betamethasone dipropionate gel in the treatment of moderately severe scalp psoriasis: a systematic review of direct and indirect evidence. Curr Med Res Opin. 2011 Jan;27(1):251-68. Resumo

61. Guenther L, Lynde C, Poulin Y. Off-label use of topical calcineurin inhibitors in dermatologic disorders. J Cutan Med Surg. 2019 Sep/Oct;23(4 Suppl):27S-34S. Resumo

62. Lebwohl M, Freeman AK, Chapman MS, et al. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol. 2004 Nov;51(5):723-30. Resumo

63. National Institute for Health and Care Excellence. Psoriasis: assessment and management. September 2017 [internet publication].Texto completo

64. Gisondi P, Altomare G, Ayala F, et al. Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2017 May;31(5):774-90.Texto completo  Resumo

65. Smith CH, Yiu ZZN, Bale T, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. Br J Dermatol. 2020 Oct;183(4):628-37.Texto completo  Resumo

66. Lapolla W, Yentzer BA, Bagel J, et al. A review of phototherapy protocols for psoriasis treatment. J Am Acad Dermatol. 2011 May;64(5):936-49. Resumo

67. Elmets CA, Lim HW, Stoff B, et al. Joint American Academy of Dermatology – National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. J Am Acad Dermatol. 2019 Sep;81(3):775-804.Texto completo  Resumo

68. van der Kraaij GE, Balak DMW, Busard CI, et al. Highlights of the updated Dutch evidence- and consensus-based guideline on psoriasis 2017. Br J Dermatol. 2019 Jan;180(1):31-42.Texto completo  Resumo

69. Prey S, Paul C. Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review. Br J Dermatol. 2009 Mar;160(3):622-8. Resumo

70. Maza A, Montaudie H, Sbidian E, et al. Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis. J Euro Acad Dermatol Venereol. 2011;25(suppl 2):19-27. Resumo

71. Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015 Jul;73(1):37-49.Texto completo  Resumo

72. Van Voorhees AS, Stein Gold L, Lebwohl M, et al. Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study. J Am Acad Dermatol. 2020 Jul;83(1):96-103.Texto completo  Resumo

73. Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015 Dec;173(6):1387-99.Texto completo  Resumo

74. Atwan A, Ingram JR, Abbott R, et al. Oral fumaric acid esters for psoriasis. Cochrane Database Syst Rev. 2015 Aug 10;2015(8):CD010497.Texto completo  Resumo

75. Nast A, Amelunxen L, Augustin M, et al. S3 guideline for the treatment of psoriasis vulgaris, update: short version part 1 - systemic treatment. J Dtsch Dermatol Ges. 2018 May;16(5):645-69. Resumo

76. Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology - National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020 Jun;82(6):1445-86.Texto completo  Resumo

77. National Institute for Health and Care Excellence. Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis. August 2014 [internet publication].Texto completo

78. Griffiths CE, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010 Jan 14;362(2):118-28.Texto completo  Resumo

79. Thaçi D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015 Sep;73(3):400-9.Texto completo  Resumo

80. Kamata M, Tada Y. Safety of biologics in psoriasis. J Dermatol. 2018 Mar;45(3):279-86. Resumo

81. Deodhar A, Mease PJ, McInnes IB, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther. 2019 May 2;21(1):111.Texto completo  Resumo

82. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008 Jan;58(1):106-15. Resumo

83. Paller AS, Siegfried EC, Langley RG, et al; Etanercept Pediatric Psoriasis Study Group. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med. 2008 Jan 17;358(3):241-51.Texto completo  Resumo

84. Carrascosa JM, Rebollo F, Gómez S, et al. Effects of etanercept on the patient-perceived results (PROs) in patients with moderate-to-severe plaque psoriasis: systematic review of the literature and meta-analysis. J Dermatolog Treat. 2018 Dec;29(8):806-11. Resumo

85. Feldman SR, Gottlieb AB, Bala M, et al. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. Br J Dermatol. 2008 Sep;159(3):704-10. Resumo

86. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008 Mar;158(3):558-66. Resumo

87. Lebwohl M, Blauvelt A, Paul C, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). J Am Acad Dermatol. 2018 Aug;79(2):266-76.Texto completo  Resumo

88. Gordon KB, Warren RB, Gottlieb AB, et al. Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2). Br J Dermatol. 2021 Apr;184(4):652-62.Texto completo  Resumo

89. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008 May 17;371(9625):1665-74. Resumo

90. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008 May 17;371(9625):1675-84. Resumo

91. Zhu X, Zheng M, Song M, et al. Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS). J Drugs Dermatol. 2013 Feb;12(2):166-74. Resumo

92. Kimball AB, Papp KA, Wasfi Y, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol. 2013 Dec;27(12):1535-45. Resumo

93. National Institute for Health and Care Excellence. Guselkumab for treating moderate to severe plaque psoriasis. June 2018 [internet publication].Texto completo

94. Reich K, Armstrong AW, Foley P, et al. Maintenance of response through up to 4 years of continuous guselkumab treatment of psoriasis in the VOYAGE 2 phase 3 study. Am J Clin Dermatol. 2020 Dec;21(6):881-90. Resumo

95. Augustin M, Lambert J, Zema C, et al. Effect of risankizumab on patient-reported outcomes in moderate to severe psoriasis: the UltIMMa-1 and UltIMMa-2 randomized clinical trials. JAMA Dermatol. 2020 Dec 1;156(12):1344-53.Texto completo  Resumo

96. Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017 Jul 15;390(10091):276-88. Resumo

97. Langley RG, Elewski BE, Lebwohl MN, et al. Secukinumab in plaque psoriasis - results of two phase 3 trials. Engl J Med. 2014 Jul 24;371(4):326-38.Texto completo  Resumo

98. Ordenes-Cavieres G, Andino-Navarrete R. Secukinumab for plaque psoriasis. Medwave. 2018 Nov 30;18(7):e7364.Texto completo  Resumo

99. Torres T, Balato A, Conrad C, et al. Secukinumab drug survival in patients with psoriasis: a multicenter, real-world, retrospective study. J Am Acad Dermatol. 2019 Jul;81(1):273-5.Texto completo  Resumo

100. Gordon KB, Blauvelt A, Papp KA, et al; UNCOVER-1 Study Group; UNCOVER-2 Study Group; UNCOVER-3 Study Group. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016 Jul 28;375(4):345-56. Resumo

101. Papp KA, Reich K, Paul C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016 Aug;175(2):273-86. Resumo

102. Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015 Oct;373(14):1318-28. Resumo

103. Puig L, Lebwohl M, Bachelez H, et al. Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial. J Am Acad Dermatol. 2020 Feb;82(2):352-9.Texto completo  Resumo

104. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019 Apr;80(4):1029-72.Texto completo  Resumo

105. Cohen AD, Vender R, Naldi L, et al. Biosimilars for the treatment of patients with psoriasis: a consensus statement from the Biosimilar Working Group of the International Psoriasis Council. JAAD Int. 2020 Nov 23;1(2):224-30.Texto completo  Resumo

106. García-Beloso N, Altabás-González I, Samartín-Ucha M, et al. Switching between reference adalimumab and biosimilars in chronic immune-mediated inflammatory diseases: a systematic literature review. Br J Clin Pharmacol. 2021 Oct 8 [Epub ahead of print]. Resumo

107. Chen X, Yang M, Cheng Y, et al. Narrow-band ultraviolet B phototherapy versus broad-band ultraviolet B or psoralen-ultraviolet A photochemotherapy for psoriasis. Cochrane Database Syst Rev. 2013 Oct 23;(10):CD009481.Texto completo  Resumo

108. Montaudie H, Sbidian E, Paul C, et al. Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity. J Europ Acad Dermatol Venereol. 2011 May;25(suppl 2):12-8. Resumo

109. Paul C, Gallini A, Maza A, et al. Evidence-based recommendations on conventional systemic treatments in psoriasis: systematic review and expert opinion of a panel of dermatologists. J Eur Acad Dermatol Venereol. 2011 May;25 (Suppl 2):2-11. Resumo

110. Elmets CA, Leonardi CL, Davis DMR, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019 Apr;80(4):1073-113.Texto completo  Resumo

111. Shah K, Mellars L, Changolkar A, et al. Real-world burden of comorbidities in US patients with psoriasis. J Am Acad Dermatol. 2017 Aug;77(2):287-92.Texto completo  Resumo

112. Dowlatshahi EA, Wakkee M, Arends LR, et al. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. J Invest Dermatol. 2014 Jun;134(6):1542-51.Texto completo  Resumo

113. Phan K, Onggo J, Charlton O, et al. Relationship between psoriasis and non-alcoholic fatty liver disease: updated systematic review and adjusted meta-analysis. Australas J Dermatol. 2019 Nov;60(4):e352-5. Resumo

114. International Psoriasis Council. IPC statement on COVID-19 and psoriasis. September 2020 [internet publication].Texto completo

115. Gelfand JM, Armstrong AW, Bell S, et al. National Psoriasis Foundation COVID-19 task force guidance for management of psoriatic disease during the pandemic: version 1. J Am Acad Dermatol. 2020 Dec;83(6):1704-16.Texto completo  Resumo

116. National Institute for Health and Care Excellence. COVID-19 rapid guideline: dermatological conditions treated with drugs affecting the immune response. April 2021 [internet publication].Texto completo

117. Mahil SK, Dand N, Mason KJ, et al. Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. J Allergy Clin Immunol. 2021 Jan;147(1):60-71.Texto completo  Resumo

118. Robbins K, Bissonnette R, Maeda-Chubachi T, et al. Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis. J Am Acad Dermatol. 2019 Mar;80(3):714-21. Resumo

119. Stein Gold L, Bhatia N, Tallman AM, et al. A phase 2b, randomized clinical trial of tapinarof cream for the treatment of plaque psoriasis: secondary efficacy and patient-reported outcomes. J Am Acad Dermatol. 2021 Mar;84(3):624-31.Texto completo  Resumo

120. Papp KA, Menter MA, Abe M, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol. 2015 Oct;173(4):949-61.Texto completo  Resumo

121. Bachelez H, van de Kerkhof PC, Strohal R, et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet. 2015 Aug 8;386(9993):552-61. Resumo

122. Asahina A, Etoh T, Igarashi A, et al. Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: a randomized, double-blind, phase 3 study. J Dermatol. 2016 Aug;43(8):869-80.Texto completo  Resumo

123. Kerschbaumer A, Smolen JS, Nash P, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. RMD Open. 2020 Nov;6(3):e001374.Texto completo  Resumo

124. Tian F, Chen Z, Xu T. Efficacy and safety of tofacitinib for the treatment of chronic plaque psoriasis: a systematic review and meta-analysis. J Int Med Res. 2019 Jun;47(6):2342-50.Texto completo  Resumo

125. Papp K, Gordon K, Thaçi D, et al. Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. N Engl J Med. 2018 Sep 11;379(14):1313-21. Resumo

126. Armstrong A, Gooderham M, Warren RB, et al. POS1042 efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, compared with placebo and apremilast in moderate to severe plaque psoriasis: results from the phase 3 POETYK PSO-1 study. Ann Rheum Dis. 2021 May;80 (Suppl 1):795-6.Texto completo

127. Reich K, Warren RB, Lebwohl M, et al. Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med. 2021 Jul 8;385(2):142-52. Resumo

128. Kurd SK, Troxel AB, Crits-Christoph P, et al. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010 Aug;146(8):891-5.Texto completo  Resumo

129. Gelfand JM, Shin DB, Neimann AL, et al. The risk of lymphoma in patients with psoriasis. J Invest Dermatol. 2006 Oct;126(10):2194-201.Texto completo  Resumo

130. Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc. 2013 Apr 4;2(2):e000062.Texto completo  Resumo

131. Tobin AM, Veale DJ, Fitzgerald O, et al. Cardiovascular disease and risk factors in patients with psoriasis and psoriatic arthritis. J Rheumatol. 2010 Jul;37(7):1386-94. Resumo

132. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol. 2013 Apr;68(4):654-62. Resumo

133. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol. 2013 Jan;149(1):84-91. Resumo

134. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes. 2012 Dec 3;2(12):e54.Texto completo  Resumo

135. Khalid U, Hansen PR, Gislason GH, et al. Psoriasis and new-onset diabetes: a Danish nationwide cohort study. Diabetes Care. 2013 Aug;36(8):2402-7.Texto completo  Resumo

136. Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006 Nov;55(5):829-35. Resumo

137. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006 Oct 11;296(14):1735-41. Resumo

O uso deste conteúdo está sujeito ao nosso aviso legal